Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).
about
Site-Specific PEGylation of Therapeutic ProteinsTherapeutic alpha-interferons protein: structure, production, and biosimilar.Monolith disk chromatography separates PEGylated protein positional isoforms within minutes at low pressure.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic responseOptimized clinical performance of growth hormone with an expanded genetic codeAdvances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeuticsEnhancing Pharmacokinetics, Tumor Accumulation, and Antitumor Efficacy by Elastin-Like Polypeptide Fusion of Interferon Alpha.Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway.Bioimaging of Hyaluronate-Interferon α Conjugates Using a Non-Interfering Zwitterionic FluorophoreBlocking LIF action in the uterus by using a PEGylated antagonist prevents implantation: a nonhormonal contraceptive strategy.Pegylated IFNs for chronic hepatitis C: an update.PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteinsProduct development issues for PEGylated proteins.The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis.Peginterferon α in the treatment of chronic hepatitis B.Improved biological and transcriptional activity of monopegylated interferon-alpha-2a isomers.Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic.Process Chemistry in Antiviral Research.Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.The role of consensus interferon in the current treatment of chronic hepatitis C viral infection.Determination of the molecular weight of poly(ethylene glycol) in biological samples by reversed-phase LC-MS with in-source fragmentation.Immunogenicity of branched polyethylene glycol modified interferon alpha.GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.
P2860
Q26777819-7AAFB502-FFEF-49DF-ACB8-FDB5D75B1075Q30361968-B2538E74-41A3-42F7-B8C1-9F4AB281C7F5Q33466665-0AD9CF41-9296-4F3A-8713-6782F84C5D23Q33559298-91D6126E-6F8F-4756-BF63-61D3B43ABAE0Q33619866-83CEAF46-01E4-45BA-9F9C-E6AD15BAB911Q33769085-FA36EC9E-6AF8-4A68-A76E-671CD21F8267Q33901953-91D7125D-D169-48B2-8477-424D87FBDDC5Q35223810-5D5EA6E7-49C4-403B-AFA9-53DB2ABD353AQ35805537-0C8FA827-C738-44A4-9B20-A2A370EF9E55Q36007339-255A77B3-8EFD-43E3-B920-47E54EE65EEDQ36155858-1F9E0F6C-647E-45F1-A5F7-251FB27F8AD7Q36288587-795B41FD-E3A4-42E6-9B59-7AF76F1D4E76Q36316698-6E8F9336-1F08-4FB4-912F-C1315D361745Q37025675-0CB13983-42F1-4D45-91F2-473CE6919320Q37790702-27035421-8F0C-4B0C-847F-3496CE3B6EF4Q37982063-7D621D8B-078E-4139-84C4-CF2C783DAA9EQ38205028-D439C729-9A63-40AF-9902-2CCFFE27FC97Q38348919-0D586E9A-20F5-4947-A2B3-7A28F2D63228Q38584280-76C60FA1-DFB8-4723-9A60-B9BF914989C8Q38997200-1D321DD0-295B-4473-98A6-2C67898CEC1FQ40481236-D35B5EA6-B7DA-4CCA-8AF0-1C9CA6F0FD69Q42233325-A7168CF5-9C23-4574-AFA1-1C8F85C81BF8Q43493861-728D0F08-7ADA-4F69-9F10-C1684C36932BQ47657406-872D584F-5158-4733-9E9F-CAD1976BEEEBQ54464834-6EADACEF-22AC-42AF-8666-F711F9422B65
P2860
Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Isolation, structural characte ...... interferon alpha-2a (PEGASYS).
@en
Isolation, structural characte ...... interferon alpha-2a (PEGASYS).
@nl
type
label
Isolation, structural characte ...... interferon alpha-2a (PEGASYS).
@en
Isolation, structural characte ...... interferon alpha-2a (PEGASYS).
@nl
prefLabel
Isolation, structural characte ...... interferon alpha-2a (PEGASYS).
@en
Isolation, structural characte ...... interferon alpha-2a (PEGASYS).
@nl
P2093
P1476
Isolation, structural characte ...... interferon alpha-2a (PEGASYS).
@en
P2093
Alfred Schacher
Doris Brugger
Elke Dietel
Karl A Weyer
Stefan Foser
Stefan Marti
Thomas Schreitmüller
P356
10.1016/S1046-5928(03)00055-X
P577
2003-07-01T00:00:00Z